Skip to main content


RheumNow Podcast – with Special Guest Dr. Peter Nash (9.15.2023)

Sep 15, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.

Read Article
Anifrolumab targets type I IFN pathway. In #SLE Trials, pts on ANIF had as much as 8-fold higher rate of Herpes zoster. HZ incidence is 6.9 vs 1.5/100 PYs on ANIF vs PBO. Other drugs may affect IFN - sifalimumab litifilimab, daxdilimab, deucravacitinib

Hard Decisions in RA (9.1.2023)

Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article

Gut Microbiome Differences Antedate JIA Development

Aug 28, 2023

Researchers have shown that gut microbiome differences may be associated with later development of juvenile idiopathic arthritis (JIA), and that such differences are present years before the disease is diagnosed.

Read Article

Stable Safety Outcomes with Abatacept

Aug 16, 2023

The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns. 

Read Article

Patient Perspectives on Telemedicine Use During the Pandemic

Aug 08, 2023

Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. During the pandemic era there was rapid adoption of telemedicine by rheumatologists; and a recent study of patient perspectives shows that most found telemedicine to be at

Read Article

Altered Gut Biome in Inflammatory Arthritis

MedPage Today
Aug 01, 2023

Another study has confirmed that the intestinal microbiome's composition in people with inflammatory arthritis differs from that in other people, and in potentially unhealthy ways -- but whether the microbiome alterations actually cause arthritis is less clear.  In fact, the investigators

Read Article

WHO Safety Study of Five TNF Inhibitors

Jul 25, 2023

Large scale analysis of adverse events (AEs) in World Health Organization (WHO) VigiAccess database showed no new safety signals associated with long-standing use of five TNFα inhibitors. 

The retrospective study analyzed AEs obtained from WHO-VigiAccess and ascribed to tumor necrosis

Read Article
US claims data shows the incidence rate of Herpes zoster (HZ) to be higher in RA (21.5/1000PY;HR 1.93) than non-RA (7.6/1000PY), increasing with age in RA,≥ 65 yrs -23.4/1000PY), highest w/ steroids and JAK inhibitors

Infectious Risk with B Cell Therapies in Lupus

Jul 19, 2023

A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.

Read Article

Hold the Methotrexate for One Week

Jul 18, 2023

In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with

Read Article
Review of DMARDs on the immunogenicity of vaccines by Winthrop: - reduced by B cell depletion, MMF, CTX, AZA, ABA - no effect: IL-6 inhibitors & HCQ - MTX & steroids: gen suppressed by depends on dose & vaccine type

Anti-Drug Antibodies with Biologics (7.14.2023)

Jul 14, 2023

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Read Article

RA Biologics Lower COVID-19 Deaths, but Not Recovery Time

Jul 11, 2023

Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?

Findings  A randomized, double-masked, placebo-controlled master protocol clinical trial found that treatment with abatacept ABA),

Read Article

ICYMI: Drug Safety Differences with New Novel Therapies in RA

Jul 06, 2023

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular

Read Article

Gut Microbiome Alterations in Lupus Patients

Jun 27, 2023

Recurrent bouts of systemic lupus erythematosus, marked by the body’s immune system attack of its own tissues, closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.

Read Article
Medicare and Commercial claims analysis shows 1 #RA pts at risk for H Zoster 2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ 3 Higher total costsalso higher in month after HZ

What is Colchicine Worth? (6.23.2023)

Jun 22, 2023

Dr. Jack Cush reviews the news and reports from the past week on This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

  1. An RCT of 1136 newly COVID test positive pts compared long term outcomes if immediately

Read Article

Abatacept Safety Outcomes Across 7 European Registries

Jun 19, 2023

A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.

Read Article

Zoster protection for JAK inhibitor patients appears achievable

Jun 07, 2023

One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster. While our patients experience outsized morbidity from zoster, it has not been clear if herpes zoster vaccination is effective in them - but data at EULAR 2023 have

Read Article
Use of antîmalarials in RA reduced the risk of bacterial infection in RA, smaller number of viral and fungal to study impact on systematic infections Bredemeier M, Abst#OP223 #EULAR2023 @RheumNow
The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8) Use of TNFi & orthopedic implants associated w/ OAI risk Mortality however similar in RA and non RA groups @RheumNow #EULAR23 POS0033
You need to see this! Albert with a Left V1 distribution of #shingles is a ‘bot’ who interacts with #rheumatologists at #EULAR2023 ⁦@RheumNow⁩ ⁦@eular_org⁩ #artificial #intelligence
Don’t be ‘rash’, get adult immune compromised Pts vaccinated against #shingles #varicella #zoster K Winthrop has research re #HZ #vaccination with #Shingrix in #Upadacitinib at #EULAR2023 #OP0225 Bottom line-get #immunecompromised Pts with #rheumatoidarthritis jabbed! @RheumNow
An interesting biomarker in #sJIA- helps differentiate it from other diseases, including infections and other inflammatory diseases! - kids with fever! serum calprotectin (MRP8/14) particle enhanced immuno-turbidimeteic assay (sCAL Turbi). 650 pts @rheumnow #EULAR2023 abst#OP0034